The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis

Leukemia

Volumn 27, Issue 7, 2013, Pages 1461-1468

  Osaki, H ^a   Walf Vorderwulbecke V ^a   Mangolini, M ^a   Zhao, L ^a   Horton, S J ^b,c   Morrone, G ^c   Schuringa, J J ^b,d   De Boer, J ^a   Williams, O ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

AML; Apoptosis; MLL AF9; Telomerase

Indexed keywords

ADENOSINE TRIPHOSPHATASE; SHORT HAIRPIN RNA; TELOMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENESIS; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLONOGENESIS; CONTROLLED STUDY; FUSION GENE; GENE EXPRESSION; GENE SILENCING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; UMBILICAL CORD BLOOD;

ADENOSINE TRIPHOSPHATASES; ANIMALS; APOPTOSIS; CARRIER PROTEINS; CELL LINE, TRANSFORMED; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DNA HELICASES; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, BIPHENOTYPIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; RNA INTERFERENCE; TELOMERASE;

EID: 84880257809     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.42     Document Type: Article

References (46)

1. Krivtsov AV, Feng Z, Armstrong SA. Transformation from committed progenitor to leukemia stem cells. Ann N Y Acad Sci 2009; 1176: 144-149.
2. Somervaille TCP, Cleary ML. Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells? Int J Hematol 2010; 91: 735-741.
3. Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated selfrenewal program as essential for leukemia maintenance. Genes Dev 2011; 25: 1628-1640.
4. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003; 17: 2298-2307.
5. Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Martin ME, Fuchs U et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004; 24: 617-628.
6. Horton SJ, Grier DG, McGonigle GJ, Thompson A, Morrow M, De Silva I et al. Continuous MLL-ENL expression is necessary to establish a "Hox Code" and maintain immortalization of hematopoietic progenitor cells. Cancer Res 2005; 65: 9245-9252.
7. Horton SJ, Walf-Vorderwulbecke V, Chatters SJ, Sebire NJ, de Boer J, Williams O. Acute myeloid leukemia induced by MLL-ENL is cured by oncogene ablation despite acquisition of complex genetic abnormalities. Blood 2009; 113: 4922-4929.
8. Slany RK. When epigenetics kills: MLL fusion proteins in leukemia. Hematol Oncol 2005; 23: 1-9.
9. Liedtke M, Cleary ML. Therapeutic targeting of MLL. Blood 2009; 113: 6061-6068.
10. Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol 2012; 7: 283-301.
11. Hess JL, Bittner CB, Zeisig DT, Bach C, Fuchs U, Borkhardt A et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood 2006; 108: 297-304.
12. Grigoletto A, Lestienne P, Rosenbaum J. The multifaceted proteins Reptin and Pontin as major players in cancer. Biochim Biophys Acta 2011; 1815: 147-157.
13. Blanc JF, Lalanne C, Plomion C, Schmitter JM, Bathany K, Gion JM et al. Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics 2005; 5: 3778-3789.
14. Rousseau B, Menard L, Haurie V, Taras D, Blanc JF, Moreau-Gaudry F et al. Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology 2007; 46: 1108-1118.
15. Maslon MM, Hrstka R, Vojtesek B, Hupp TR. A divergent substrate-binding loop within the pro-oncogenic protein anterior gradient-2 forms a docking site for Reptin. J Mol Biol 2010; 404: 418-438.
16. Ren J, Li W, Liu H, Yan L, Jiao W, Li D et al. Overexpression of Reptin in renal cell carcinoma contributes to tumor malignancies and its inhibition triggers senescence of cancer cells. Urol Oncol 2012 (in press).
17. Menard L, Taras D, Grigoletto A, Haurie V, Nicou A, Dugot-Senant N et al. In vivo silencing of Reptin blocks the progression of human hepatocellular carcinoma in xenografts and is associated with replicative senescence. J Hepatol 2010; 52: 681-689.
18. Adler HT, Chinery R, Wu DY, Kussick SJ, Payne JM, Fornace Jr AJ et al. Leukemic HRX fusion proteins inhibit GADD34-induced apoptosis and associate with the GADD34 and hSNF5/INI1 proteins. Mol Cell Biol 1999; 19: 7050-7060.
19. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissuespecific expression of transgenes delivered by lentiviral vectors. Science 2002; 295: 868-872.
20. Petrella A, Doti I, Agosti V, Giarrusso PC, Vitale D, Bond HM et al. A 5' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells. Blood 1998; 91: 4554-4560.
21. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-813.
22. Woodward MJ, de Boer J, Heidorn S, Hubank M, Kioussis D, Williams O et al. Tnfaip8 is an essential gene for the regulation of glucocorticoid-mediated apoptosis of thymocytes. Cell Death Differ 2010; 17: 316-323.
23. Mezard C, Davies AA, Stasiak A, West SC. Biochemical properties of RuvB(D113N): a mutation in helicase motif II of the RuvB hexamer affects DNA binding and ATPase activities. J Mol Biol 1997; 271: 704-717.
24. Wood MA, McMahon SB, Cole MD. An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. Mol Cell 2000; 5: 321-330.
25. Menssen A, Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci USA 2002; 99: 6274-6279.
26. Kim J, Woo AJ, Chu JL, Snow JW, Fujiwara Y, Kim CG et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010; 143: 313-324.
27. Venteicher AS, Meng ZJ, Mason PJ, Veenstra TD, Artandi SE. Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell 2008; 132: 945-957.
28. Li W, Zeng J, Li Q, Zhao L, Liu T, Bjorkholm M et al. Reptin is required for the transcription of telomerase reverse transcriptase and over-expressed in gastric cancer. Mol Cancer 2010; 9: 132.
29. Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, Wilhelm JS et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 2008; 13: 483-495.
30. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
31. Gallant P. Control of transcription by pontin and reptin. Trends Cell Biol 2007; 17: 187-192.
32. Etard C, Gradl D, Kunz M, Eilers M, Pontin WedlichD. and Reptin regulate cell proliferation in early Xenopus embryos in collaboration with c-Myc and Miz-1. Mech Dev 2005; 122: 545-556.
33. Si J, Yu X, Zhang Y, DeWille JW. Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression. Mol Cancer 2010; 9: 92.
34. Hoverter NP, Waterman MLA. Wnt-fall for gene regulation: repression. Sci Signal 2008; 1: pe43.
35. Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, Tran C et al. Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature 2005; 434: 921-926.
36. Olson LE, Tollkuhn J, Scafoglio C, Krones A, Zhang J, Ohgi KA et al. Homeodomainmediated beta-catenin-dependent switching events dictate cell-lineage determination. Cell 2006; 125: 593-605.
37. Schreiner S, Birke M, Garcia-Cuellar MP, Zilles O, Greil J, Slany RK. MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation. Cancer Res 2001; 61: 6480-6486.
38. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
39. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLLfusion leukaemia. Nature 2011; 478: 529-533.
40. Wang YZ, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng ZH et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650-1653.
41. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D et al. Betacatenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010; 18: 606-618.
42. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010; 31: 9-18.
43. Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 2011; 11: 161-176.
44. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
45. Gessner A, Thomas M, Castro PG, Buchler L, Scholz A, Brummendorf TH et al. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia 2010; 24: 1751-1759.
46. Suzuki H, Forrest AR, van Nimwegen E, Daub CO, Balwierz PJ, Irvine KM et al. The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet 2009; 41: 553-562.